SARS-CoV-2 accessory proteins involvement in inflammatory and profibrotic processes through IL11 signaling

SARS-CoV-2, the cause of the COVID-19 pandemic, possesses eleven accessory proteins encoded in its genome. Their roles during infection are still not completely understood. In this study, transcriptomics analysis revealed that both and were significantly up-regulated in A549 cells expressing individ...

Full description

Saved in:
Bibliographic Details
Published in:Frontiers in immunology Vol. 14; p. 1220306
Main Authors: López-Ayllón, Blanca D, de Lucas-Rius, Ana, Mendoza-García, Laura, García-García, Tránsito, Fernández-Rodríguez, Raúl, Suárez-Cárdenas, José M, Santos, Fátima Milhano, Corrales, Fernando, Redondo, Natalia, Pedrucci, Federica, Zaldívar-López, Sara, Jiménez-Marín, Ángeles, Garrido, Juan J, Montoya, María
Format: Journal Article
Language:English
Published: Switzerland Frontiers Media S.A 20-07-2023
Subjects:
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:SARS-CoV-2, the cause of the COVID-19 pandemic, possesses eleven accessory proteins encoded in its genome. Their roles during infection are still not completely understood. In this study, transcriptomics analysis revealed that both and were significantly up-regulated in A549 cells expressing individual accessory proteins ORF6, ORF8, ORF9b or ORF9c from SARS-CoV-2 (Wuhan-Hu-1 isolate). IL11 is a member of the IL6 family of cytokines. IL11 signaling-related genes were also differentially expressed. Bioinformatics analysis disclosed that both and were involved in pulmonary fibrosis idiopathic disease and functional assays confirmed their association with profibrotic cell responses. Subsequently, data comparison with lung cell lines infected with SARS-CoV-2 or lung biopsies from patients with COVID-19, evidenced altered profibrotic gene expression that matched those obtained in this study. Our results show ORF6, ORF8, ORF9b and ORF9c involvement in inflammatory and profibrotic responses. Thus, these accessory proteins could be targeted by new therapies against COVID-19 disease.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
These authors have contributed equally to this work and share senior authorship
Reviewed by: Boris Michael Hartmann, Österreichische Agentur für Gesundheit und Ernährungssicherheit, Austria; Shetty Ravi Dyavar, Adicet Bio, Inc., United States; Matt Johansen, University of Technology Sydney, Australia
Edited by: Pei-Hui Wang, Shandong University, China
ISSN:1664-3224
1664-3224
DOI:10.3389/fimmu.2023.1220306